Literature DB >> 18189332

BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.

A Perez-Rosado1, Mj Artiga, P Vargiu, A Sanchez-Aguilera, A Alvarez-Barrientos, Ma Piris.   

Abstract

BCL6 is a transcriptional repressor whose deregulated expression plays a key role in diffuse large B-cell lymphomas (DLBCLs). BCL6 expression characterizes one of the two main subtypes (GC type) of DLBCL, while the other (ABC type) is recognized by increased NFkappaB activation. The mechanistic basis of this distinction remains unclear and the BCL6 targets have been only partially explored. Here we describe how NFkappaB activity is increased after BCL6 silencing by shRNA in DLBCL cells, leading us to propose that BCL6 represses NFkappaB activity. We also demonstrate that this repression is brought about by a mechanism involving protein-protein interaction between BCL6 and NFkappaB members, both in vitro and in vivo. Analysis of a series of DLBCLs shows a negative correlation between the expression of NFkappaB target genes and BCL6. This combined approach using silenced cells and a series of human DLBCL samples leads us to a better understanding of the role of BCL6 as an NFkappaB regulator in B-cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18189332     DOI: 10.1002/path.2279

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  23 in total

Review 1.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 2.  NF-kappaB pathways in the immune system: control of the germinal center reaction.

Authors:  Christine A Goetz; Albert S Baldwin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 3.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

4.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

5.  YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.

Authors:  Shuai Ye; Matthew A Lawlor; Adrian Rivera-Reyes; Shaun Egolf; Susan Chor; Koreana Pak; Gabrielle E Ciotti; Avery C Lee; Gloria E Marino; Jennifer Shah; David Niedzwicki; Kristy Weber; Paul M C Park; Md Zahidul Alam; Alison Grazioli; Malay Haldar; Mousheng Xu; Jennifer A Perry; Jun Qi; T S Karin Eisinger-Mathason
Journal:  Cancer Res       Date:  2018-02-28       Impact factor: 12.701

6.  p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.

Authors:  Alexis Proust; Patricia Rincé; Rita Creidy; Thierry Lazure; Irène Joab; Loïc Garçon; Monique Fabre; Catherine Guettier; Martine Raphael
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

7.  High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.

Authors:  F Kreisel; S Kulkarni; R T Kerns; A Hassan; H Deshmukh; R Nagarajan; J L Frater; A Cashen
Journal:  Cancer Genet       Date:  2011-03

8.  AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.

Authors:  Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages.

Authors:  Maliheh Nazari-Jahantigh; Yuanyuan Wei; Heidi Noels; Shamima Akhtar; Zhe Zhou; Rory R Koenen; Kathrin Heyll; Felix Gremse; Fabian Kiessling; Jochen Grommes; Christian Weber; Andreas Schober
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

Review 10.  EBV-positive diffuse large B-cell lymphoma of the elderly.

Authors:  Chi Young Ok; Thomas G Papathomas; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.